<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6146">
  <stage>Registered</stage>
  <submitdate>19/10/2016</submitdate>
  <approvaldate>19/10/2016</approvaldate>
  <nctid>NCT02943239</nctid>
  <trial_identification>
    <studytitle>Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women</studytitle>
    <scientifictitle>A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacodynamics Effects of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002979-95</secondaryid>
    <secondaryid>R2477-1033-HV-1621</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - REGN1033
Treatment: drugs - REGN2477
Other interventions - Placebo

Experimental: Panel A - REGN1033 + REGN2477 (Regimen 1) or placebo

Experimental: Panel B - Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo

Experimental: Panel C - Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo

Experimental: Panel D - Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo


Treatment: drugs: REGN1033
REGN1033

Treatment: drugs: REGN2477
REGN2477

Other interventions: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence and severity of treatment-emergent adverse events (TEAEs) - Incidence and severity of treatment-emergent adverse events (TEAEs)</outcome>
      <timepoint>From baseline to week 16</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in thigh muscle volume as measured by MRI - Percent change in thigh muscle volume as measured by MRI</outcome>
      <timepoint>From baseline to week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in thigh muscle volume as measured by MRI - Change in thigh muscle volume as measured by MRI</outcome>
      <timepoint>From baseline to week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in total and regional body composition as measured by DXA - Percent change in total and regional body composition as measured by DXA</outcome>
      <timepoint>From baseline to week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total body composition as measured by DXA - Change in total body composition as measured by DXA</outcome>
      <timepoint>From baseline to week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in regional body composition as measured by DXA - Change in regional body composition as measured by DXA</outcome>
      <timepoint>From baseline to week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile of REGN2477 assessed via measurement of concentrations of REGN2477 in serum over time - Pharmacokinetic profile of REGN2477</outcome>
      <timepoint>From baseline to week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile of REGN1033 assessed via measurement of concentrations of REGN1033 in serum overtime - Pharmacokinetic profile of REGN1033</outcome>
      <timepoint>From baseline to week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total Activin A levels in blood - Change in total Activin A levels in blood</outcome>
      <timepoint>From baseline to week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total GDF8 levels in blood - Change in total GDF8 levels in blood</outcome>
      <timepoint>From baseline to week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence or absence of antibodies against REGN2477 and REGN1033 - Presence or absence of antibodies against REGN2477 and REGN1033</outcome>
      <timepoint>From baseline to week 16</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Postmenopausal women age 45 to 70 years

          -  BMI between 18 to 32 kg/m2, inclusive

          -  Willing and able to maintain current diet, supplements and physical activity level
             throughout the study

          -  Provides signed informed consent</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Significant illness or history of significant illness

          -  Contraindication to MRI

          -  History of human immunodeficiency virus (HIV); hepatitis B or hepatitis C virus (HCV)

          -  History of immobilization, major surgical procedure, fracture, or major trauma within
             9 months prior to screening

          -  History of significant gynecological disorders or malignancies; history of breast
             malignancies (uterine fibroids or dysfunctional uterine bleeding is acceptable)

          -  Inconsistent vigorous physical activity (on fewer than 5 days per week), such as
             intermittent weight lifting

          -  History of hypersensitivity reactions to tetracycline antibiotics (includes
             doxycycline), vaccines, or biologics

          -  Use of agents that alter muscle mass that have not been at a stable dose for 3 months
             prior to screening (includes protein supplements), or use of any weight altering or
             anabolic steroid drugs (includes drugs for obesity, diuretics, testosterone)

          -  Patients treated with a biologic therapy or biologic immunotherapy in the previous 12
             weeks prior to screening and during the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Regeneron Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Assess the safety and tolerability of REGN2477 alone and combined with REGN1033 in health
      postmenopausal women.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02943239</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trial Management</name>
      <address>Regeneron Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Trials Administrator</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@regeneron.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>